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The cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase type I (cGKI) pathway regulates many
cellular functions. The current study shows that 8-Br-cGMP stimulates the number of attached primary but not that of
subcultured murine vascular smooth muscle cells (VSMCs). These effects of 8-Br-cGMP require the presence of cGKI. In
agreement with previous studies, cGKI inhibited the number of cells in repeatedly passaged murine VSMCs. Activation
of the cGMP/cGKI pathway in freshly isolated primary VSMCs slightly decreased apoptosis and strongly increased cell
adhesion. The stimulation of cell adhesion by cGKI involves an inhibition of the RhoA/Rho kinase pathway and
increased exposure of 1 and 3 integrins on the cell surface. Together, these results identify a novel proadhesive function
of cGMP/cGKI signaling in primary VSMCs and suggest that the opposing effects of this pathway on VSMC number
depend on the phenotypic context of the cells.
INTRODUCTION
The nitric oxide (NO)/cyclic guanosine monophosphate
(cGMP)/cGMP-dependent protein kinase type I (cGKI)
pathway regulates important functions in many cell types,
including vascular smooth muscle cells (VSMCs) (Feil et al.,
2003; Lohmann and Walter, 2005; Hofmann et al., 2006;
Lincoln et al., 2006). In addition to its potent vasorelaxant
properties, it has been associated with vascular proliferative
diseases, such as atherosclerosis and restenosis (von der
Leyen et al., 1995; Janssens et al., 1998; Varenne et al., 1998;
von der Thusen et al., 2004). Several studies (an excellent
summary is given in Lincoln et al., 2006) suggested that
activation of cGKI-dependent pathways has antimitogenic
effects in smooth muscle cells (SMCs) in culture (Garg and
Hassid, 1989; Boerth et al., 1997; Chiche et al., 1998; Brophy
et al., 2002) and might be vasculoprotective in the intact
animal (Anderson et al., 2000; Sinnaeve et al., 2002). De-
spite a large body of evidence that active cGKI acts anti-
proliferative, Hassid and coworkers reported that NO/
cGMP amplified the proliferative response of fibroblast
growth factor-2 in primary VSMCs (Hassid et al., 1994).
These results were supported by a report that NO and
cGMP analogues activated rather than inhibited the mi-
togen-activated protein (MAP) kinase pathway in freshly
isolated rat aortic VSMCs (Komalavilas et al., 1999). An
increased MAP kinase activity has been associated with
an increase in cell proliferation. The antiproliferative ef-
fect of cGMP/cGKI signaling could not be confirmed by a
study on atherosclerosis in an in vivo mouse model (Wolf-
sgruber et al., 2003). This study suggested a proathero-
genic role of VSMC cGKI. Furthermore, the recent analy-
sis of several murine models for restenosis did not show
significant effects of the presence or absence of cGKI in
VSMCs on restenosis (Lukowski et al., 2008).
Previous in vitro and in vivo studies led to the hypothesis
that cGKI may affect different functions in primary and
cultured VSMCs. A loss or reduction of cGKI, as it may
occur during passage of VSMCs, is associated with the de-
velopment of a synthetic phenotype (reviewed in Lincoln et
al., 2006). Because the inhibitory effects of cGKI on cell
number were observed predominantly in passaged VSMCs,
whereas the stimulatory effect of cGKI was found in primary
VSMCs (Wolfsgruber et al., 2003), the contrary findings
might depend on the phenotype of the VSMCs, i.e., synthetic
versus contractile smooth muscle cells.
In the present study, we analyzed the modulatory effects
of cGMP on cell number in primary and passaged aortic
VSMCs from control and cGKI-deficient mice (Wegener et
al., 2002). We conclude that cGKI acts antiproliferative on
passaged VSMCs, whereas it promotes the cell number of
freshly isolated VSMCs primarily via stimulation of cell
adhesion.
This article was published online ahead of print in MBC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08–04–0370)
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MATERIALS AND METHODS
Materials
8-Bromoguanosine-3, 5-cyclic monophosphate was purchased from Biolog
(Hayward, CA), U-46619 was from Alexis Laboratories (San Diego, CA), and
H1152 was from Calbiochem (San Diego). Blocking antibodies against 1 and
3 integrins (Schultz and Armant, 1995; Ridger et al., 2001) were purchased
from Biolegend (San Diego, CA) (CD29, CD61). All other reagents and chem-
icals were purchased from Roth (Karlsruhe, Germany), Invitrogen (Carlsbad,
CA), or Sigma-Aldrich (St. Louis, MO).
Mouse Breeding
Wild-type, heterozygous, and homozygous cGKI knockout mice were ob-
tained as described previously (Pfeifer et al., 1998; Wegener et al., 2002; Weber
et al., 2007). The animals used in this work were generated from heterozygous
cGKI/L mice on a 129/Sv genetic background (Wegener et al., 2002).
VSMCs isolated from wild-type (cGKI/) and heterozygous (cGKI/L)
mice showed identical results, and they were thus used as controls (ctr).
Animals were handled according to German animal protection law.
Cell Culture
Aortic VSMCs were isolated from control mice (cGKI/ and cGKI/L) and
cGKI knockout (ko) mice (cGKIL/L) by enzymatic digestion and grown in
DMEM (Invitrogen) supplemented with 10% fetal calf serum (FCS) (Invitro-
gen) and 1% Pen/Strep (Invitrogen) at 37°C and 6% CO2 as described previ-
ously (Kuhbandner et al., 2000; Wolfsgruber et al., 2003). To establish subcul-
tures, primary VSMCs were grown to 80–90% confluence, trypsinized,
counted, and replated at a density of 200,000 cells/100-mm cell culture dish
for further passaging.
Determination of Cell Number
To determine the cell number of attached cells, VSMCs were plated in 96-well
plates (primary cells at 20,000 cells/well and passaged cells at 5000 cells/well)
and cultured for 3 d in the absence and presence of drugs. If not stated
otherwise, drugs were added before plating. The number of attached cells was
determined by the CellTiter 96 AQ–NonRadioactive Cell Proliferation Assay
(MTS assay) (Promega, Madison, WI), which is an indirect method of cell
quantification and involves the bioreduction of a tetrazolium salt by living
cells to a colored formazan product. The assay was used according to the
manufacturer’s protocol. Briefly, after cells were washed once with serum-
free medium, 100 l of serum-free medium was added to each well followed
by 20 l of MTS solution and incubation at 37°C and 6% CO2. The OD495 was
measured after 30 and 60 min by using a plate reader (Titertek Multiscan
MCC/340; Titertek, Huntsville, AL). To validate the results obtained with
the MTS assay, the toluidine blue (TB) assay was performed subsequently to
the MTS assay by using the same wells. Staining of cells with TB is a more
direct measure of cell number compared with the MTS assay. Cells were fixed
and stained with TB solution (0.5% TB, 2% formaldehyde, and 0.2% glutar-
aldehyde in phosphate-buffered saline [PBS]) for 10 min at room temperature.
Then, excessive TB solution was removed by five successive washing steps
with PBS. Finally, the cells were destained in 100 l of 1% SDS, and the OD620
was measured. Both assays gave comparable results, supporting the signifi-
cance of our experiments. To analyze integrin-mediated adhesion, integrin
blocking antibodies were added to the cells before plating. For each experi-
ment a 24-well plate was treated accordingly to confirm the obtained values
by microscopy.
For the analysis of cell attachment kinetics, freshly isolated VSMCs from
control and cGKI-deficient animals were seeded at a density of 125,000
cells/ml in a -Dish35 mm, low with Grid-500 (ibidi) in the absence and pres-
ence of 100 M 8-Br-cGMP. Pictures were taken 4 h after seeding the cells and
subsequently every 24 h. Five representative fields of view were analyzed for
each condition and point in time.
Time-Lapse Microscopy
Freshly isolated VSMCs (125,000) were cultured in a 24 well plate for each
condition in 1 ml of CO2-free medium (Invitrogen) supplemented with 10%
FCS, 2 mM l-glutamine, and 1% Pen/Strep. Cell kinetics was recorded for
72 h in the absence and presence of 1 mM 8-Br-cGMP. Recording was
started 4 h after seeding to allow sedimentation of the cells. The micro-
scope stage and the surrounding were kept at 37°C.
RhoA Activity Assay
RhoA activity was determined by the G-Lisa assay (Cytoskeleton, Denver,
CO) according to the manufacturer’s manual. To stimulate RhoA activity,
cells were treated with the thromboxane mimetic U-46619 at 3 M for 5 min
before lysis.
Flow Cytometry
To detect apoptotic cells, a human annexin V fluorescein isothiocyanate
(FITC) kit (Bender MedSystems, Vienna, Austria) was used according to the
manufacturer’s protocol. Briefly, freshly isolated primary VSMCs were incu-
bated in a Falcon tube (200,000 cells/ml) in DMEM supplemented with 10%
FCS at 37°C and 6% CO2 in the absence and presence of 1 mM 8-Br-cGMP.
Immediately after isolation, and after 4, 6, 10, and 24 h, aliquots of 100,000
cells were taken, stained with FITC-labeled annexin V and propidium iodide
(PI), and subjected to flow cytometry by using a FACSCalibur (BD Bio-
sciences, San Jose, CA). Cells (10,000) of each sample were counted, and data
were analyzed with Cell Quest Pro (4.62). Annexin V-positive and PI-negative
cells were considered apoptotic and used for statistical analysis.
To analyze integrin exposure on the cell surface, freshly isolated primary
VSMCs were incubated for 24 h in DMEM supplemented with 10% FCS at
37°C and 6% CO2 in the absence and presence of 1 mM 8-Br-cGMP. Then,
150,000 cells were stained with antibodies against 1 or 3 integrins followed
by a secondary FITC-labeled antibody and flow cytometry (in 5% FCS in PBS,
pH 7.4). Dead cells were excluded by PI staining. Cells (10,000) per sample
were counted, and data were analyzed with CellQuest Pro 4.62 (BD Bio-
sciences).
Immunocytochemistry
Cells were plated on glass coverslips in a 24-well plate at a cell density of
100,000 cells/well. After 2 to 3 d of culture, cells were washed twice with PBS
and fixed in 3.7% Formalin in PBS. Subsequently, cells were permeabilized
with ice-cold (20°C) acetone for 5 min, washed with 1% bovine serum
albumin in PBS and incubated with 5% normal goat serum in PBS for 10 min.
VSMCs were stained for vinculin (Sigma-Aldrich) for 45 min. After three
washing steps, cells were incubated with an appropriate fluorescence-labeled
secondary antibody (Alexa 488) for 30 min. For F-actin staining, cells were
stained with rhodamine-phalloidin (Invitrogen). After staining, the cells were
embedded in Mowiol (Calbiochem) with p-phenylendiamine (Sigma-Al-
drich). Photomicrographs were taken with a confocal microscope (TCS NT
[Leica, Wetzlar, Germany] or LSM 510 [Carl Zeiss, Jena, Germany]).
Western Blot
To analyze the phosphorylation of vasodilator-stimulated phosphoprotein
(VASP), 100,000 cells/well were seeded in a six-well culture plate. Cells were
grown to 80–90% confluence, and then they were serum starved for 48 h and
treated with different compounds for 30 min in serum-free medium. Cells
were harvested with lysis buffer (21 mM Tris HCl, pH 8.0, 0.7% SDS, 1.7%
-mercaptoethanol, and 0.2 mM phenylmethylsulfonyl fluoride) followed by
Western blot analysis using antibodies for cGKI (Pfeifer et al., 1998), -actin
(Abcam, Cambridge, MA), and VASP (Alexis Laboratories). For detection of
RhoA (Santa Cruz Biotechnology, Santa Cruz, CA) expression, primary
VSMCs were cultured for 3 d in the absence and presence of 100 M
8-Br-cGMP.
Statistics
If not otherwise reported, experiments were reproduced at least three times
with similar results. Data are presented as mean  SEM (n  6–8) per
experiment. Most data were analyzed with Origin Pro 6.1 software (Origin-
Lab, Northampton, MA). To compare groups, an unpaired Student’s t test
was used. Apoptosis was analyzed by two-way analysis of variance by using
the Prism 4.0 software (GraphPad Prism Software, San Diego, CA). Signifi-
cance levels were ns, not significantly different; and *, **, and *** denote
significant differences at p  0.05, p  0.01, and p  0.001, respectively.
RESULTS
cGKI Promotes Recovery of Primary VSMCs in Culture
Murine primary aortic VSMCs were incubated under stan-
dard culture conditions. The number of cells was compared
after 72-h incubation in the presence of different compounds.
The number of viable attached cells was determined by
using a colorimetric NonRadioactive Cell Proliferation As-
say (CellTiter 96 AQ; Promega) and toluidine blue staining.
Quantitative results were confirmed by microscopy (e.g.,
Figure 2B), which could exclude increase in cell size as major
cause for increased cell number. Concentrations of 0.1 and 1
mM 8-Br-cGMP were chosen for cell treatment according to
a dose–response curve of 8-Br-cGMP on cell attachment
(Supplemental Figure 1).
The number of murine primary aortic VSMCs was not
affected by the presence or absence of cGKI under standard
culture conditions (Supplemental Figure 2), indicating that
cGKI is dispensable for basal adhesion. Addition of the
membrane-permeable cGMP analogue 8-Br-cGMP signifi-
cantly increased the number of primary VSMCs in the pres-
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ence but not in the absence of cGKI (Figure 1A). Similar
results were obtained when 8-Br-cGMP was replaced by the
cGMP analogues 8-Br-PET-cGMP or 8-pCPT-cGMP (data
not shown). In contrast, 8-Bromoadenosine-3, 5-cyclic
monophosphate (8-Br-cAMP), a stimulator of cAMP-depen-
dent protein kinase (cAK), reduced the number of primary
and subcultured VSMCs in a cGKI-independent manner
(Figure 1, A and B). In line with previous reports (Garg and
Hassid, 1989; Boerth et al., 1997; Chiche et al., 1998; Brophy et
al., 2002), 8-Br-cGMP acts antiproliferative on passaged mu-
rine VSMCs in a cGKI-dependent manner (Figure 1B). The
inhibitory effect of cGKI in subcultured murine cells was
relatively weak and became statistically significant after five
passages of the VSMCs (Figure 1, B and C). Interestingly, the
strong cGKI-dependent increase in cell number in primary
cells is already lost with the first passage (Figure 1C). The
differential effects of 8-Br-cGMP on cell number of primary
versus subcultured murine VSMCs was not due to a change
in cGKI expression or enzyme activity during subculture as
monitored by Western blot analysis of cGKI and phosphor-
ylation of its substrate VASP (Figure 1, D and E, and Sup-
plemental Figure 3). The phosphorylation of VASP, which is
also a substrate of cAK, in response to 8-Br-cAMP was weak
compared with 8-Br-cGMP-induced phosphorylation in con-
trol cells. This could be explained by the chosen stimulatory
conditions that were optimized for cGKI-induced phosphor-
ylation of VASP.
Because there is a plethora of literature describing a loss of
cGKI expression during passaging (Cornwell and Lincoln,
1989; Boerth et al., 1997), the obtained results for murine
VSMCs were compared with VSMCs derived from rat and
human to exclude an species specific effect (Supplemental
Figure 4). Subcultured rat (Supplemental Figure 4A) as well
as subcultured human (Supplemental Figure 4B) SMCs ex-
pressed cGKI. Furthermore, as revealed by phosphorylation
of VASP, cGKI was still active.
cGKI Promotes Cell Number of Primary VSMCs by
Increasing Adhesion
The above-mentioned experiments clearly demonstrated
that an activation of cGKI increased the number of attached
viable cells after 3 d in primary culture (Figure 1A). This
effect of cGKI could be caused by several mechanisms, in-
cluding 1) an antiapoptotic effect of cGKI; 2) a promitogenic
effect, i.e., a proliferative response; and/or 3) an increased
number of cells adhering to the culture dish. Activation of
cGKI slightly but significantly decreased apoptosis during
the initial time period (24 h) after isolation of the cells from
the aorta (Figure 2A). This finding was unexpected, because
a proapoptotic effect of cGKI has been reported in SMCs
(Chiche et al., 1998). However, the observed antiapoptotic
effect was too small to explain the two- to threefold increase
in the number of primary VSMCs attached to the culture
dish after 72 h in the presence of 8-Br-cGMP (Figure 1A). To
dissect the potential effects of cGMP on cell adhesion and/or
proliferation, the attachment of freshly isolated VSMCs was
monitored by time-lapse microscopy during the first 72 h
after plating. Whereas dividing cells were not observed dur-
ing this period, treatment with 8-Br-cGMP strongly in-
creased the fraction of adherent cells (Figure 2B). Note
that equal amounts of cells were plated in the absence and
presence of 8-Br-cGMP (Figure 2B). To proof the cGKI-
mediated increase in cell adhesion in control cells and to
rule out the effect in cGKI-deficient VSMCs, the time-lapse
experiment was repeated in an alternative approach.
Freshly isolated VSMCs from control and cGKI-deficient
animals were seeded in a -Dish, and attachment of cells
was documented by taking photomicrographs every 24 h
(Supplemental Figure 5). The detailed analysis of this
experiment confirmed a cGKI-mediated increased adhe-
sion; hence, the absence of a proadhesive effect in re-
sponse to 8-Br-cGMP in the cGKI-deficient cells (Supple-
mental Figure 5). The identical results of these two
alternative approaches exclude the possibility that the
observed effect is caused by the chosen method.
The proadhesive effect of 8-Br-cGMP was accompanied by
the occurrence of stress fibers and focal adhesions as visu-
alized by staining of fixed cells for F-actin and vinculin,
respectively. These cytoskeletal changes in response to 8-Br-
cGMP could not be observed in cGKI-deficient cells (Figure
3A). To exclude a proliferative effect and to strengthen the
observed effect of cGKI on cell adhesion, VSMCs were al-
lowed to attach in the absence of 8-Br-cGMP for 3 d. Subse-
Figure 1. Cell culture of control (ctr) and cGKI-deficient (ko) pri-
mary and subcultured VSMCs. Number of attached cells of primary
(A) and subcultured passage 5 (B) VSMCs. Cell number was mea-
sured in the absence (H2O) and presence of 8-Br-cGMP (100 M) or
8-Br-cAMP (100 M) and normalized to control conditions (H2O).
(C) cGKI-mediated growth of VSMCs in culture. Growth perfor-
mance of primary (P0) up to passage 11 (P11) VSMCs in response to
8-Br-cGMP (100 M) (MTS assay). Cell number was normalized to
control. (D and E) Phosphorylation of VASP in response to 8-Br-
cGMP (100 M) and 8-Br-cAMP (100 M) in primary (D) and
subcultured passage 5 (E) VSMCs. An antibody against cGKI was
used to demonstrate the presence and absence of cGKI protein. Akt
was used as loading control. See Materials and Methods for further
details.
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quently, adherent cells were exposed to 8-Br-cGMP for fur-
ther 3 d. A slight, although significant increase in cell
number could be observed (Figure 3B), confirming a previ-
ous observation (Wolfsgruber et al., 2003). These results
indicated that the cGMP/cGKI-stimulated increase in cell
number at 72 h of primary culture was mainly due to an
increase in the efficiency of cell adhesion rather than to an
effect on cell proliferation or apoptosis.
Adhesion of Primary VSMCs Is Mediated by Inhibition of
the RhoA/Rho Kinase Pathway
Cell adhesion is regulated by a number of signaling path-
ways, including the RhoA/Rho kinase pathway (Ridley and
Hall, 1992; Rottner et al., 1999; Worth et al., 2004). The small
GTPase RhoA is a known substrate of cGKI (Sauzeau et al.,
2003; Rolli-Derkinderen et al., 2005). As expected from a
previous report (Sauzeau et al., 2003), treatment of primary
VSMCs with 8-Br-cGMP increased the amount of total RhoA
protein in control but not in cGKI-deficient cells (Figure 4A),
indicating that activation of cGKI increased the RhoA con-
centration. This effect on the RhoA protein level could be
mediated via phosphorylation of RhoA at Ser188, thereby
possibly affecting RhoA activity by stabilization of an inac-
tive, cytosolic RhoA-guanosine triphosphate (GTP)/GDP
dissociation inhibitor (GDI) complex (Sauzeau et al., 2000;
Rolli-Derkinderen et al., 2005). Indeed, activation of RhoA
via the thromboxane receptor agonist U-46619 (Wetts-
chureck and Offermanns, 2005; Rieken et al., 2006) was effi-
ciently blocked in the presence of 8-Br-cGMP (Figure 4B), as
shown previously (Sauzeau et al., 2000; Seko et al., 2003). In
line with a role of RhoA in VSMC adhesion, the number of
adhering primary cells was suppressed by U-46619. Impor-
tantly, 8-Br-cGMP prevented the inhibitory effect of U-46619
in control but not cGKI-deficient cells (Figure 4C). The an-
tiadhesive effect of U-46619 treatment was also reflected by
a strong reduction in F-actin and vinculin staining (Figure
4D). These results support the notion that the proadhesive
effect of cGMP/cGKI is mediated, at least in part, via inhi-
bition of RhoA signaling.
A well characterized downstream target of RhoA is Rho
kinase. Inhibition of this kinase has been reported to increase
cell adhesion (Koga et al., 2006). Addition of the Rho kinase
inhibitor H1152 to the primary VSMCs mimicked the effects
of 8-Br-cGMP on cell number and morphology (Figure 5).
Similar results were obtained with Y27632, another well
known Rho kinase inhibitor (data not shown). The observa-
tions that coapplication of 8-Br-cGMP and H1152 did not
cause an additive effect (Figure 6C) and that H1152 also led
to an increase in cell number of cGKI-deficient cells (Figure
5A) suggested that cGKI and Rho kinase are components of
the same pathway and that Rho kinase acts downstream of
cGKI.
cGKI-stimulated Adhesion Is Mediated via Integrins
It is generally accepted that adhesion of cells is linked to
integrins (Schwartz et al., 1995; Berrier and Yamada, 2007).
To analyze whether integrins are also involved in cGKI-
mediated adhesion, primary VSMCs derived from control
and cGKI-deficient mice were labeled for 1 and 3 inte-
grins, two integrins that are known to be important for
adhesion. Both integrins could be detected on the cell sur-
face by flow cytometry. Addition of 8-Br-cGMP increased
the mean fluorescence signal for 1 and 3 integrins, indi-
cating an increase in integrin presentation at the cell mem-
brane. This effect could only be detected in control but not in
cGKI-deficient cells (Figure 6A). To determine whether 1
and/or 3 integrins were functionally involved in cGKI-
dependent adhesion of primary VSMCs, the number of at-
tached cells was analyzed in the presence of 1 and/or 3
blocking antibodies. As shown in Figure 6B, 8-Br-cGMP–
stimulated adhesion was reduced by antibodies against 1
as well as 3 integrin. Moreover, coadministration of both
antibodies resulted in an additive effect and abolished the
proadhesive effect of 8-Br-cGMP. Importantly, the integrin-
blocking antibodies decreased the proadhesive stimulation
Figure 2. Analysis of apoptosis and cell attachment kinetics. (A)
Analysis of apoptosis of primary control and cGKI-deficient
VSMCs. Representative original measurements of primary control
VSMCs after 6 h in suspension in the absence (H2O) and presence of
8-Br-cGMP (1 mM). Cells were labeled with Annexin V and PI. The
time course of the appearance of apoptotic cells (Annexin V-positive
and PI-negative) in control and cGKI-deficient cell preparations is
shown in the bottom diagrams. (B) Analysis of cell number and
attachment by time-lapse videomicroscopy. VSMCs were plated in
the absence (H2O) and presence of 8-Br-cGMP (1 mM) and moni-
tored for 72 h. Representative pictures are shown at the indicated
times. Arrows highlight individual cells during the time of obser-
vation. The number of adherent and floating cells in the absence and
presence of 8-Br-cGMP was determined for each microscopic field
(bottom).
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elicited by the Rho kinase inhibitor H1152 to a similar extent
(Figure 6C), corroborating the view that cGMP/cGKI stim-
ulates integrin exposure and cell adhesion via inhibition of
Rho kinase.
DISCUSSION
cGKI is an important regulator of many smooth muscle
functions, including VSMC growth, adhesion, proliferation,
and apoptosis (Hofmann et al., 2006; Lincoln et al., 2006).
Many in vitro studies demonstrated an antiproliferative ef-
fect of cGMP and cGKI signaling in subcultured VSMCs
(Garg and Hassid, 1989; Hassid et al., 1994; Li and Sun, 2005),
VSMC-derived cell lines (Capey et al., 2007) or VSMCs that
have been transfected with cGKI (Boerth et al., 1997;
Browner et al., 2004; Dey et al., 2005). In agreement with
these studies, we find that activation of the cGMP/cGKI
pathway slightly inhibited proliferation of passaged murine
VSMCs. In passaged murine VSMCs, the mechanism(s)
leading to a reduction in cell number by cGMP is not clear.
Inhibition was not associated with a loss of cGKI or its
activity and in fact required the presence of cGKI. Further-
more, it is important to note that control and cGKI-deficient
VSMCs showed similar basal properties and phenotypes
Figure 3. Analysis of cell adhesion and proliferation. (A) Cytoskeletal staining of primary control and cGKI-deficient VSMCs. Cells were
grown on glass coverslips for 24 and 48 h in the absence (H2O) or presence of 8-Br-cGMP (1 mM). VSMCs were stained for F-Actin (red) and
vinculin (green) as marker for focal adhesions. Photographs were taken with a confocal microscope (TCS NT; Leica). (B) Primary VSMCs were
grown for 72 h under control conditions. Subsequently, 8-Br-cGMP (100 M) was added for additional 72 h.
Figure 4. Adhesion of VSMCs is mediated by inhi-
bition of RhoA. (A) Western blot analysis of total
RhoA protein. Primary control (ctr) and cGKI-defi-
cient (ko) VSMCs were grown in the absence (H2O)
and presence of 8-Br-cGMP (100 M) for 72 h. Cells
were harvested, and protein lysates were subjected
to Western blot (left). -Actin was used as loading
control. RhoA expression was quantified using the
AIDA software by normalizing each RhoA band to
its respective loading control (n  7 ctr; n  3 ko).
The ratio of the values obtained after 8-Br-cGMP
treatment to those after H2O treatment is expressed
as Expression [n-fold] (right). (B) G-Lisa RhoA assay.
RhoA activity (RhoA-GTP) was determined in pri-
mary control VSMCs that were grown for 72 h in the
absence (H2O) or presence of 8-Br-cGMP (100 M).
Cells were treated with U-46619 (3 M) 5 min before
lysis to increase RhoA-GTP levels as indicated. All
values (n  3 for each condition) were normalized to
control (H2O). (C) Primary control (ctr) and cGKI-
deficient (ko) VSMCs were grown for 72 h in the
absence (H2O) and presence of 8-Br-cGMP (100 M)
and/or U-46619 (3 M) as indicated. The number of
cells was determined by the MTS assay. (D) Primary
control cells were grown for 72 h in the absence
(H2O) or presence of 8-Br-cGMP (100 M) or
U-46619 (3 M) and then stained for F-actin (red),
vinculin (green), and DNA (Hoechst). White bar, 50
m. Photographs were taken with a confocal micro-
scope (LSM 510; Carl Zeiss).
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under standard culture conditions (Supplemental Figure 2
and Figure 3A). These results suggest that the phenotypic
modulation of VSMCs during passages requires unknown
factors in addition to a potential change in cGKI expression
level.
In contrast to passaged VSMCs, the present work clearly
demonstrates that cGKI activation increases the number of
attached primary, freshly isolated VSMCs. The cGMP/
cGKI-dependent increase in cell number was mainly medi-
ated via an increase in cell adhesion as shown by 1) time-
lapse microscopy, 2) enhanced exposure of integrin 1 and
3 on the cell surface; and 3) inhibition of enhanced adhesion
by antibodies that block 1 and 3 integrins. The proadhe-
sive effect is the major cause of the cGKI-dependent increase
in the number of primary VSMCs after 72 h in culture. The
anti-apoptotic (Figure 2A) and proproliferative (Figure 3B)
properties of the cGMP/cGKI pathway had a minor, al-
though significant effect on the cell number.
The effect of cGMP/cGKI-signaling on apoptosis is dis-
cussed controversial. In SMCs, cGKI has been reported to
have a proapoptotic effect (Pollman et al., 1996; Chiche et al.,
1998). In contrast, an antiapoptotic effect of cGKI has been
documented for neuronal cells (Fiscus, 2002; Ha et al., 2003).
The different results reported for SMCs might be related to
the major differences in the chosen cell system. In contrast to
our study, Chiche et al. (1998) used subcultured cells that
were transfected with cGKI. The newly identified role for
cGKI to increase adhesion of primary VSMCs might repre-
sent a protective mechanism against anoı̈kis. It is well ac-
cepted that adhesion to the extracellular matrix is necessary
for survival of differentiated adherent cells in the cardiovas-
cular system, including endothelial cells, smooth muscle
cells, fibroblasts, and cardiac myocytes (Michel, 2003).
Figure 6. cGKI-dependent adhesion is mediated by 1 and 3 inte-
grins. (A) Analysis of integrin surface exposure by flow cytometry.
Labeling of 1 and 3 integrins on primary control VSMCs that were
grown for 24 h in suspension in the absence (H2O) or presence of
8-Br-cGMP (1 mM). The control cells show an increased mean fluores-
cence signal for 3 integrins in response to 8-Br-cGMP (left). The
statistic evaluation of the 1 and 3 integrin signal in control (ctr) and
cGKI-deficient (ko) VSMCs in response to 8-Br-cGMP is shown (right).
Data shown were from one out of three experiments with similar
results. Each experiment consisted of six independent samples. Values
represent the change in fluorescence in the presence of 8-Br-cGMP
compared with control (H2O). (B) Integrin-mediated adhesion of primary
control VSMCs in response to 8-Br-cGMP. The MTS-assay was performed
with primary VSMCs that were grown for 72 h in the absence or presence
of 8-Br-cGMP (1 mM) and integrin blocking antibodies (25 g/ml) as
indicated. Cell numbers were normalized to the value obtained in the
absence of compounds. Increased adhesion in response to 8-Br-cGMP is
significantly reduced upon treatment with either  integrin blocking an-
tibody. (C) Comparison of integrin-mediated adhesion of primary control
VSMCs in response to 8-Br-cGMP and H1152. Primary control VSMCs
were grown for 72 h in the absence or presence of 8-Br-cGMP (1 mM) or
H1152 (0.3 M) and integrin blocking antibodies (25 g/ml each) as
indicated. Cell number was assayed by the TB method and normalized to
the value obtained in the absence of compounds.
Figure 5. Adhesion of VSMCs is mediated by inhibition of Rho
kinase. (A) Cell number of primary control (ctr) and cGKI-deficient
(ko) VSMCs in the absence (H2O) and presence of 8-Br-cGMP (100
M) or H1152 (0.3 M). (B) Photographs of primary control cells
were taken with a confocal microscope (LSM 510; Carl Zeiss) after
72 h in culture in the absence (H2O) and presence of 8-Br-cGMP (100
M) or H1152 (0.3 M). Cells were stained for F-actin (red), vinculin
(green), and DNA (Hoechst). The merge of F-actin and vinculin
staining is yellow. White bar, 50 m.
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Therefore, it is likely that cGKI exerts different effects in
primary and passaged VSMCs.
The cGKI is known to relax smooth muscle by several
mechanisms, including inhibition of Ca2 sensitization of
contraction via inhibition of RhoA/Rho kinase signaling
(Somlyo and Somlyo, 2003). This article adds a novel role to
the interaction between the cGMP/cGKI and the RhoA/Rho
kinase signaling pathways in murine VSMCs. Activation of
cGKI inhibits RhoA/Rho kinase signaling, resulting in in-
creased adhesion via 1 and 3 integrins of primary murine
VSMCs. It is well accepted that RhoA/Rho kinase is in-
volved in cell adhesion (Ridley and Hall, 1992; Burridge and
Wennerberg, 2004). Here, we provide strong evidence that
cGKI stimulates the attachment of primary, freshly isolated
VSMCs by inhibition of the RhoA/Rho kinase pathway. The
effects of 8-Br-cGMP and the Rho kinase inhibitor H1152 on
cell number were not additive, and the effects of pharmaco-
logic manipulation of RhoA and Rho kinase were indepen-
dent of the genotype. In contrast, activation of cGKI effi-
ciently suppressed RhoA activation by the thromboxane
receptor agonist U-46619 as well as the U-46619-induced de-
crease of the number of attached cells. These results suggest
that cGMP/cGKI and RhoA/Rho kinase are components of the
same signaling pathway and converge in regulating cell adhe-
sion. cGKI is downstream of the thromboxane receptor but acts
upstream of RhoA and Rho kinase. Indeed, cGKI has been
reported to phosphorylate and thereby stabilize the RhoA pro-
tein in an inactive RhoA-GTP/GDI complex, leading to an
increase in total RhoA protein (Sauzeau et al., 2000; Rolli-
Derkinderen et al., 2005).
Whether RhoA stimulates or inhibits adhesion seems to
depend on the cell type and culture conditions (Ridley and
Hall, 1992; Laudanna et al., 1996; Schoenwaelder et al., 2002;
Worthylake and Burridge, 2003; Vielkind et al., 2005; Slotta et
al., 2006). Increased adhesion after blockade of Rho kinase
has also been described by others (Kim et al., 2005; Koga et
al., 2006). Koga et al. (2006) demonstrated that inhibition of
Rho kinase in human trabecular meshwork cells causes in-
creased adhesion but that it had no influence on prolifera-
tion (Koga et al., 2006). The signaling networks linking RhoA
and integrins vary according to the mode of cell growth,
such as adhesion of a floating cell to the substratum, spread-
ing, or migration (Schwartz and Shattil, 2000; Danen et al.,
2002). For example, inhibition of RhoA/Rho kinase in leu-
kocytes elevates integrin-mediated adhesion (Liu et al., 2002;
Worthylake and Burridge, 2003). The present study indicates
that a similar mechanism was observed in primary VSMCs
as shown by 1) a reduction in the number of attached cells
upon stimulation with the thromboxane receptor agonist
U-46619 that activates RhoA, 2) stimulation of the attached
cell number by inhibition of Rho kinase with H1152 or
Y27632, and 3) a decrease of the attached cell number in
response to 8-Br-cGMP or H1152 by blocking 1 and 3
integrins.
Integrins have a pivotal role in mediating processes such
as adhesion, migration, and cell–cell contacts. To allow these
different processes, the expression of integrins is tightly
regulated during development. For example in adult human
aortic VSMCs 11 integrin is highly expressed, represent-
ing a resting, contractile phenotype, and it is strongly re-
duced or lost, with the beginning of cell culture (Belkin et al.,
1990). In line with these findings, a recent study using a
conditional 1 integrin knockout model showed that the lack
of 1 integrin in VSMCs causes a synthetic phenotype (Abra-
ham et al., 2008). These data support the notion that integrins
have major impact on the phenotype of VSMCs that may be
modulated by cGKI.
In summary, we show that cGKI promotes integrin-medi-
ated adhesion of primary VSMCs by inhibiting the RhoA/
Rho kinase pathway.
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